Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors

Molecular Pharmacology

Volumn 75, Issue 4, 2009, Pages 982-990

  Pellissier, Lucie P ^a   Sallander, Jessica ^b   Campillo, Mercedes ^b   Gaven, Florence ^a   Queffeulou, Emilie ^a   Pillot, Marion ^a   Dumuis, Aline ^a   Claeysen, Sylvie ^a   Bockaert, Joël ^a,c   Pardo, Leonardo ^b  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 2,3 DIHYDRO 3 ISOPROPYL 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE; ALANINE; BENZAMIDE; CISAPRIDE; COMPLEMENTARY DNA; CYCLIC AMP; RO 1161148; SEROTONIN; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG; ZACOPRIDE;

ANIMAL CELL; ARTICLE; COMPUTER MODEL; CONFORMATIONAL TRANSITION; DOSE RESPONSE; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RADIOASSAY; RECEPTOR DENSITY; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS;

EID: 63849323943     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053686     Document Type: Article

References (41)

1. Alves ID, Salamon Z, Varga E, Yamamura HI, Tollin G, and Hruby VJ (2003) Direct observation of G-protein binding to the human δ-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem 278:48890-48897.
2. 4 receptors in neurons. Eur J Pharmacol 298:165-174.
3. Ballesteros J and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein coupled receptors, in Methods in Neurosciences 25:366-428.
4. Ballesteros JA, Deupi X, Olivella M, Haaksma EE, and Pardo L (2000) Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation. Biophys J 79:2754-2760.
5. Baneres JL, Mesnier D, Martin A, Joubert L, Dumuis A, and Bockaert J (2005) Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J Biol Chem 280:20253-20260.
6. Barthet G, Gaven F, Framery B, Shinjo K, Nakamura T, Claeysen S, Bockaert J, and Dumuis A (2005) Uncoupling and endocytosis of 5-hydroxytryptamine 4 receptors.
7. Distinct molecular events with different GRK2 requirements. J Biol Chem 280: 27924-27934.
8. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Appar-sundaram S, Hyek MF, Kenakin TP, and Allen LF (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 374:272-276.
9. Case D, Darden T, Cheatham T, Simmerling C, and Wang J (2006) AMBER 9, University of California, San Francisco, CA. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265.
11. Claeysen S, Joubert L, Sebben M, Bockaert J, and Dumuis A (2003) A single mutation in the 5-HT4 receptor (5-HT4-R D100(3.32)A) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J Biol Chem 278: 699-702.
12. Claeysen S, Sebben M, Becamel C, Bockaert J, and Dumuis A (1999) Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 55:910-920.
13. 4 receptor antagonists on constitutively active wild-type and mutated receptors. Mol Pharmacol 58:136-144.
14. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. JComput Chem 24:1999-2012.
15. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β32 adrenergic receptor. J Biol Chem 276: 24433-24436.
16. Jongejan A, Bruysters M, Ballesteros JA, Haaksma E, Bakker RA, Pardo L, and Leurs R (2005) Linking agonist binding to histamine H1 receptor activation. Nat Chem Biol 1:98-103.
17. Joubert L, Claeysen S, Sebben M, Bessis AS, Clark RD, Martin RS, Bockaert J, and Dumuis A (2002) A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem 277:25502-25511.
18. Kobilka BK (2007) G protein coupled receptor structure and activation. Biochim Biophys Acta 1768:794-807.
19. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97.
20. Li J, Edwards PC, Burghammer M, Villa C, and Schertler GF (2004) Structure of bovine rhodopsin in a trigonal crystal form. JMol Biol 343:1409-1438.
21. Lin SW and Sakmar TP (1996) Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35:11149-11159.
22. López-Rodríguez ML, Morcillo MJ, Fernández E, Benhamú B, Tejada I, Ayala D,Viso A, Campillo M, Pardo L, Delgado M, et al. (2005) Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors. J Med Chem 48:2548-2558.
23. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, and Abood ME (2004) Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 279:48024-48037.
24. McGregor MJ, Islam SA, and Sternberg MJ (1987) Analysis of the relationship between side-chain conformation and secondary structure in globular proteins. J Mol Biol 198:295-310.
25. Mialet J, Dahmoune Y, Lezoualc'h F, Berque-Bestel I, Eftekhari P, Hoebeke J, Sicsic S, Langlois M, and Fischmeister R (2000) Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling. Br J Pharmacol 130:527-538.
26. Okada T, Ernst OP, Palczewski K, and Hofmann KP (2001) Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem Sci 26: 318-324.
27. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure ofrhodopsin: a G protein-coupled receptor. Science 289:739-745.
28. Pardo L, Deupi X, Dolker N, López-Rodríguez ML, and Campillo M (2007) The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. Chembiochem 8:19-24.
29. ParkJH, Scheerer P, Hofmann KP, Choe HW, and Ernst OP (2008) Crystalstructure of the ligand-free G-protein-coupled receptor opsin. Nature 454:183-187.
30. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, et al. (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318:1266-1273.
31. Ruprecht JJ, Mielke T, Vogel R, Villa C, and Schertler GF (2004) Electron crystallography reveals the structure of metarhodopsin I. EMBO J 23:3609-3620.
32. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
33. Schertler GF (2005) Structure of rhodopsin and the metarhodopsin I photointerme-diate. Curr Opin Struct Biol 15:408-415.
34. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519.
35. Shi L and Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. AnnuRev Pharmacol Toxicol 42:437-467.
36. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, and Javitch JA (2002) β32 Adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996.
37. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, and Leurs R (2007) Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47:53-87.
38. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, and Kobilka BK (2004) Sequential binding of agonists to the β32 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 279:686-691.
39. Urizar E, Claeysen S, Deupí X, Govaerts C, Costagliola S, Vassart G, and Pardo L (2005) An activation switch in the rhodopsin family ofG protein-coupled receptors: the thyrotropin receptor. J Biol Chem 280:17135-17141.
40. Visiers I, Ballesteros JA, and Weinstein H (2002) Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 343: 329-371.
41. Wang J, Wolf RM, Caldwell JW, Kollman PA, and Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157-1174.